SWOG clinical trial number
SWOG-9452 (INT-0159) (CALGB 9480)
A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer
Closed
Phase
Published
Abbreviated Title
A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer
Activated
10/01/1996
Closed
07/15/1998
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480
2000
Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC).
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase